首页> 外文期刊>The Japanese journal of antibiotics >Surveillance of susceptibility of clinical isolates to panipenem between 2000 and 2003
【24h】

Surveillance of susceptibility of clinical isolates to panipenem between 2000 and 2003

机译:监测2000年至2003年临床分离株对Panipenem的易感性

获取原文
获取原文并翻译 | 示例
           

摘要

For the post-marketing surveillance of panipenem/betamipron (PAPM/BP, Carbenin), MICs of injectable beta-lactam antibacterials including PAPM against clinical isolates from 15 medical institutions all over Japan are measured yearly and the incidence rates of resistance in various species are also evaluated. In the first surveillance from June 2000 to March 2001, 1,356 isolates of 28 species were tested, 1,221 isolates of the same 28 species were tested in the second surveillance from April 2001 to March 2002, and 1,403 isolates of the same 28 species were tested in the third surveillance from April 2002 to March 2003. No remarkable changes in the activity of PAPM were observed in these surveillances spanning three years. The activity of PAPM in this study was comparable to that in the studies conducted before Carbenin was launched. This result suggests that PAPM still maintains potent activity. In these surveillances spanning three years, the incidence rates of resistance in various species were as follows (2000.6-2001.3 --> 2001.4-2002.3 --> 2002.4-2003.3): methicillin-resistant Staphylococcus aureus (39.3% --> 43.9% --> 47.3%), penicillin-intermediate Streptococcus pneumoniae (48.9% --> 44.2% --> 25.7%), penicillin-resistant S. pneumoniae (PRSP, 13.8% --> 26.3% --> 43.2%), extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (0.9% --> 0% --> 1.4%), ESBL-producing Klebsiella pneumoniae (3.4% --> 1.3% --> 3.1%), beta-lactamase-producing Haemophilus influenzae (19.2% --> 8.9% --> 42.9%), beta-lactamase-negative ampicillin-resistant H. influenzae (BLNAR, 22.1% --> 30.7% --> 33.0%), and metallo-beta-lactamase-producing Pseudomonas aeruginosa (1.0% --> 4.4% --> 1.0%). PAPM showed the most potent activity among tested drugs against PRSP, whose incidence rate increased notably. BLNAR, whose incidence rates also increased, exhibited low susceptibility to all tested drugs and metallo-beta-lactamase-producing P. aeruginosa also exhibited high resistance. The findings of this surveillance indicate that it is necessary to pay careful attention to the trends of resistant bacteria such as PRSP, BLNAR, and metallo-beta-lactamase producing strains.
机译:对于销售后胰岛素/贝凡脂(PAPM / BP,Carbenin)的营销监测,可注射β-内酰胺抗菌的麦克风,包括来自日本的15个医疗机构的临床分离株,每年都被测量,并且各种物种的抗性发生率为也评估。在第一次监测到2001年6月至2001年3月,测试了1,356个物种的分离株,在2001年4月至2002年4月的第二次监视中测试了1,221个分离株28种,同一28种的1,403个分离物进行了测试2002年4月至2003年3月的第三次监测。在三年的这些监测中没有观察到PAPM活动的显着变化。 PAPM在本研究中的活性与在氨基蛋白发射之前进行的研究中的研究相当。这一结果表明PAPM仍然保持有力的活动。在这些跨越三年的这些监测中,各种物种的抗性发病率如下(2000.6-2001.3 - > 2001.4-2002.3 - > 2002.4-2003.3):耐甲氧西林金黄色葡萄球菌(39.3% - > 43.9% - - > 47.3%),青霉素中间体链球菌肺炎料(48.9% - > 44.2% - > 25.7%),青霉素抗性S.肺炎(PRSP,13.8% - > 26.3% - > 43.2%),延长 - 谱β-内酰胺酶(ESBL) - 发布大肠杆菌(0.9% - 0% - > 1.4%),产生ESBL的Klebsiella肺炎(3.4% - > 1.3% - 3.1%),β-内酰胺酶 - 产生嗜血杆菌嗜血杆菌(19.2% - > 8.9% - > 42.9%),β-内酰胺酶 - 阴性氨苄青霉素H.流感(Blnar,22.1% - > 30.7% - > 33.0%)和金属 - 生产β-内酰胺酶的假单胞菌铜绿假单胞菌(1.0% - > 4.4% - > 1.0%)。 PAPM对PRSP的测试药物中最有效的活性,其发病率显着增加。 Blnar的发病率也增加,对所有测试药物和金属β-乳酰胺酶P.铜绿假单胞也表现出低敏感性。这种监视的调查结果表明,必须仔细注意抗性细菌的趋势,如PRSP,BLNAR和Metallo-β-内酰胺酶产生菌株。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号